RxDoctor Payments DataLook up a doctor →

Joseph Galati, MD

Hepatology · Houston, TXNPI 1821069162

Payments from drug & device makers

$351,594in general payments, 2019–2025

Across 799 payments — averaging $440.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$97K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$61K
  • Intercept Pharmaceuticals, Inc.$61K
  • Gilead$51K
  • Madrigal Pharmaceuticals$25K
  • Regeneron$19K
  • plus $38K from 30 others

What the payments were for

  • Consulting fees$12,3136%
  • Speaking & faculty fees$161,23176%
  • Grants$3,1251%
  • Travel & lodging$17,9949%
  • Food & beverage$16,4958%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$351,594 in reported general payments places this provider in the 70th percentile of 22 hepatology providers in Texas.

See all hepatology providers in Texas

Medicare billing

Part B allowed, 2024
$207,862
Medicare patients
525
Services billed
1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin331$1,134,606
OcalivaObeticholic Acid15$201,028
RezdiffraResmetirom22$97,404
VemlidyTenofovir Alafenamide38$67,783
Ursodiol247$43,161
OzempicSemaglutide29$26,177
LinzessLinaclotide13$12,045
Lactulose251$10,161
Tenofovir Disoproxil Fumarate62$6,004
Entecavir33$5,496
Spironolactone272$3,729
Azathioprine65$3,513
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C22$3,092
Pantoprazole Sodium226$2,699
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates42$2,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$61,176$1,137,698353 claims
Intercept Pharmaceuticals, Inc.Ocaliva$61,015$201,02815 claims
Madrigal PharmaceuticalsRezdiffra$24,547$97,40422 claims
GileadVemlidy$50,941$67,78338 claims
Novo NordiskOzempic$280$26,17729 claims
AbbVieLinzess$96,774$12,04513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 22 hepatology providers in Texas.

Other hepatology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →